Aptamers: a new class of oligonucleotides in the drug discovery pipeline?

Current Opinion in Pharmacology

Volumn 9, Issue 5, 2009, Pages 602-607

  Dausse, Eric ^a,b   Da Rocha Gomes, Sonia ^c   Toulmé, Jean Jacques ^a,b  

^a INSERM U869   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; ARC 127; ARC 1779; ARC 1905; AS 1411; BLOOD CLOTTING FACTOR 9A; DOCETAXEL; E 10030; FLUOROPYRIMIDINE; FOMIVIRSEN; GELONIN; MACROGOL; NOX B11; NOX E36; NU 172; NX 21909; OBLIMERSEN; OLIGOMER; OLIGONUCLEOTIDE; PEGAPTANIB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; RB 006; RB 007; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA; THROMBIN; THYMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BINDING AFFINITY; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; MOLECULAR CLONING; NONHUMAN; OBESITY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS; REVIEW; SEQUENCE ANALYSIS; THROMBOSIS;

ANIMALS; APTAMERS, NUCLEOTIDE; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MACULAR DEGENERATION; NUCLEIC ACID CONFORMATION; SELEX APTAMER TECHNIQUE; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349431228     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.07.006     Document Type: Review

References (51)

1. Werner A., Carlile M., and Swan D. What do natural antisense transcripts regulate?. RNA Biol 6 (2009) 43-48
2. Strobel S.A., and Cochrane J.C. RNA catalysis: ribozymes, ribosomes, and riboswitches. Curr Opin Chem Biol 11 (2007) 636-643
3. Chekulaeva M., and Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21 (2009) 452-460
4. Castanotto D., and Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457 (2009) 426-433
5. Eckstein F. The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7 (2007) 1021-1034. A short review indicating the minus and plusses of the different oligonucleotide strategies.
6. Toulmé J.J. New candidates for true antisense. Nat Biotechnol 19 (2001) 17-18
7. Juliano R., Alam M.R., Dixit V., and Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36 (2008) 4158-4171
8. Geary R.S., Henry S.P., and Grillone L.R. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41 (2002) 255-260
9. Tarhini A.A., and Kirkwood J.M. Oblimersen in the treatment of metastatic melanoma. Future Oncol 3 (2007) 263-271
10. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
11. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
12. Mayer G. The chemical biology of aptamers. Angew Chem Int Ed Engl 48 (2009) 2672-2689. An excellent review on chemically modified aptamers and their various applications.
13. Wilson C., and Keefe A.D. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol 10 (2006) 607-614
14. Chelliserrykattil J., and Ellington A.D. Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA. Nat Biotechnol 22 (2004) 1155-1160
15. Veedu R.N., Vester B., and Wengel J. Efficient enzymatic synthesis of LNA-modified DNA duplexes using KOD DNA polymerase. Org Biomol Chem 7 (2009) 1404-1409
16. Wlotzka B., Leva S., Eschgfaller B., Burmeister J., Kleinjung F., Kaduk C., Muhn P., Hess-Stumpp H., and Klussmann S. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A 99 (2002) 8898-8902. An interesting application of oligonucleotide enantiomers.
17. Gopinath S.C. Methods developed for SELEX. Anal Bioanal Chem 387 (2007) 171-182
18. Kaur G., and Roy I. Therapeutic applications of aptamers. Expert Opin Investig Drugs 17 (2008) 43-60
19. Khati M., Schuman M., Ibrahim J., Sattentau Q., Gordon S., and James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J Virol 77 (2003) 12692-12698
20. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., and Janjic N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273 (1998) 20556-20567
21. Helmling S., Maasch C., Eulberg D., Buchner K., Schroder W., Lange C., Vonhoff S., Wlotzka B., Tschop M.H., Rosewicz S., et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci U S A 101 (2004) 13174-13179
22. Charlton J., Kirschenheuter G.P., and Smith D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 36 (1997) 3018-3026
23. Bock L.C., Griffin L.C., Latham J.A., Vermass E.H., and Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355 (1992) 564-566. One of the first selection of DNA aptamer with an inhibitory effect against a protein with no known nucleic acid function.
24. Rusconi C.P., Scardino E., Layzer J., Pitoc G.A., Ortel T.L., Monroe D., and Sullenger B.A. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419 (2002) 90-94
25. Muller J., Freitag D., Mayer G., and Potzsch B. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 6 (2008) 2105-2112. Authors describe the selection and the optimization for biological applications of an aptamer against the factor IXa and how they designed several oligonucleotides complementary to the aptamer sequence to identify a relevant antidote under clinical conditions.
26. Kim Y., Cao Z., and Tan W. Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc Natl Acad Sci U S A 105 (2008) 5664-5669
27. Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., Horvath C.J., Merlino P.G., Marsh H.N., Healy J.M., Boufakhreddine S., Holohan T.V., and Schaub R.G. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116 (2007) 2678-2686
28. Toulmé J.J., Di Primo C., and Boucard D. Regulating eukaryotic gene expression with aptamers. FEBS Lett 567 (2004) 55-62
29. James W. Aptamers in the virologists' toolkit. J Gen Virol 88 (2007) 351-364
30. Tuerk C., Macdougal S., and Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type-1 reverse transcriptase. Proc Natl Acad Sci U S A 89 (1992) 6988-6992
31. Andréola M.L., Pileur F., Calmels C., Ventura M., Tarrago-Litvak L., Toulmé J.J., and Litvak S. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 40 (2001) 10087-10094
32. Umehara T., Fukuda K., Nishikawa F., Kohara M., Hasegawa T., and Nishikawa S. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J Biochem 137 (2005) 339-347
33. Ducongé F., Di Primo C., and Toulmé J.J. Is a closing "GA pair" a rule for stable loop-loop RNA complexes?. J Biol Chem 275 (2000) 21287-21294
34. Da Rocha Gomes S., Dausse E., and Toulmé J.J. Determinants of apical loop-internal loop RNA-RNA interactions involving the HCV IRES. Biochem Biophys Res Commun 322 (2004) 820-826
35. Di Primo C., Rudloff I., Reigadas S., Arzumanov A.A., Gait M.J., and Toulmé J.J. Systematic screening of LNA/2′-O-methyl chimeric derivatives of a TAR RNA aptamer. FEBS Lett 581 (2007) 771-774
36. Shi H., Hoffman B.E., and Lis J.T. RNA aptamers as effective protein antagonists in a multicellular organism. Proc Natl Acad Sci U S A 96 (1999) 10033-10038. A good example of in vivo biological effects induced by an in vitro selected aptamer.
37. Levy-Nissenbaum E., Radovic-Moreno A.F., Wang A.Z., Langer R., and Farokhzad O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26 (2008) 442-449
38. Yan A.C., and Levy M. Aptamers and aptamer targeted delivery. RNA Biol 6 (2009) 316-320
39. Lupold S.E., Hicke B.J., Lin Y., and Coffey D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62 (2002) 4029-4033
40. Chu T.C., Twu K.Y., Ellington A.D., and Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 34 (2006) e73
41. McNamara II J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., and Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24 (2006) 1005-1015
42. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., and Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103 (2006) 6315-6320
43. Bagalkot V., Farokhzad O.C., Langer R., and Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45 (2006) 8149-8152
44. Chu T.C., Marks III J.W., Lavery L.A., Faulkner S., Rosenblum M.G., Ellington A.D., and Levy M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 66 (2006) 5989-5992
45. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., and Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86 (2009) 151-164
46. Hicke B.J., Marion C., Chang Y.F., Gould T., Lynott C.K., Parma D., Schmidt P.G., and Warren S. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276 (2001) 48644-48654. One of the first example of aptamer targeted to a given cell type. This tenascin aptamer has been subsequently used for various purposes.
47. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., Borkowski S., Hilger C.S., Cook G., Warren S., et al. Tumor targeting by an aptamer. J Nucl Med 47 (2006) 668-678
48. Vento M.T., Iuorio M., Netti P.A., Ducongé F., Tavitian B., Franciscis V., and Cerchia L. Distribution and bioactivity of the Ret-specific D4 aptamer in three-dimensional collagen gel cultures. Mol Cancer Ther 7 (2008) 3381-3388
49. Blank M., and Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 9 (2005) 336-342
50. Cox J.C., Rudolph P., and Ellington A.D. Automated RNA selection. Biotechnol Prog 14 (1998) 845-850
51. Berezovski M., Musheev M., Drabovich A., and Krylov S.N. Non-SELEX selection of aptamers. J Am Chem Soc 128 (2006) 1410-1411